News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public
View HTML
Toggle Summary Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
The primary endpoint was met (p
View HTML
Toggle Summary Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
FREMONT, Calif. , Dec. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, December 3 , at 8:00
View HTML
Toggle Summary Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
FREMONT, Calif. , Nov. 26, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive officer of
View HTML
Toggle Summary Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
- Companies establish a research collaboration with associated options to license any resulting development candidates with the potential for up to $500 million in development and sales milestones for Ardelyx - In addition, Kyowa Kirin makes $20 million equity investment in Ardelyx FREMONT, Calif.
View HTML
Toggle Summary Ardelyx Announces Presentation at Kidney Week 2019
Late breaking oral presentation to highlight data from AMPLIFY, the Pivotal Phase 3 Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment FREMONT, Calif. , Nov. 6, 2019 /PRNewswire/ --  Ardelyx, Inc.
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
PHREEDOM clinical trial to read out this quarter FREMONT, Calif. , Nov. 6, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported
View HTML
Toggle Summary Ardelyx to Host Analyst Day in New York
Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C     FREMONT, Calif. , Oct. 10, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on
View HTML
Toggle Summary Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
FREMONT, Calif. , Sept. 17, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive
View HTML